UPDATE: Stifel Nicolaus Raises PT to $40 on Theravance on Improved Risk Profile
Stifel Nicolaus reiterated its Buy rating on Theravance (NASDAQ: THRX) and raised its price target from $28 to $40.
Stifel Nicolaus noted, "We believe recently-announced top-line P3 LAMA/LABA data implies a relatively clear regulatory path forward and our physician conversations suggest the utilization of these combined mechanisms of action should gain considerable traction/adoption in those moderate/severe COPD patients whom require prolonged/significant bronchodilation."
Therevance closed at $29.49 on Friday.
Latest Ratings for THRX
|May 2015||Cowen & Co.||Downgrades||Market Perform|
|Jul 2014||Bank of America||Downgrades||Buy||Neutral|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.